What are the effects and risks of prolonged benzodiazepine infusion in an adult intensive‑care patient?

Effects of Prolonged Benzodiazepine Infusion in ICU Patients

Prolonged benzodiazepine infusions in adult ICU patients cause delayed emergence from sedation, increased delirium risk, propylene glycol toxicity (with lorazepam), drug accumulation with active metabolites, and worse clinical outcomes including prolonged mechanical ventilation and ICU length of stay. 1

Primary Adverse Effects

Delayed Awakening and Drug Accumulation

• Prolonged administration saturates peripheral tissues, leading to unpredictable and extended emergence times 1
• Midazolam shows greater variability and longer awakening times compared to lorazepam with prolonged use, despite lorazepam's slower clearance 1
• Active metabolites of midazolam and diazepam accumulate, especially in renal dysfunction, further prolonging sedation 1
• Awakening times can extend to 44.6 hours in renal failure patients versus 13.6 hours in those without renal impairment 2
• Patients with combined hepatic and renal failure may take over 120 hours to awaken 2

Delirium Risk

Continuous benzodiazepine infusions significantly increase delirium risk (OR 1.04 per 5mg midazolam equivalent, 95% CI 1.03-1.06), while intermittent dosing does not show this association 3. This effect is independent of disease severity and other delirium risk factors 3.

Two major RCTs demonstrated that dexmedetomidine reduces delirium prevalence by ~20% daily compared to benzodiazepine infusions 1. The 2013 PAD guidelines specifically recommend dexmedetomidine over benzodiazepines for sedation in delirious ICU patients (excluding alcohol/benzodiazepine withdrawal) 1.

Propylene Glycol Toxicity (Lorazepam-Specific)

Lorazepam formulations contain propylene glycol as a diluent, causing metabolic acidosis and acute kidney injury 1. This toxicity can occur at doses as low as 1 mg/kg/day, not just the previously thought 15-25 mg/hr 1.

Monitor serum osmol gap: values >10-12 mOsm/L indicate significant propylene glycol accumulation 1.

Tolerance Development

Tolerance develops with long-term administration, requiring escalating doses to maintain the same sedation level 1, 2. This creates a vicious cycle of increasing drug exposure and accumulation.

High-Risk Populations

Elderly Patients

• Significantly more sensitive to benzodiazepine sedative effects 1
• Decreased clearance with advancing age 1
• Higher risk of cognitive impairment and falls

Organ Dysfunction

• Hepatic dysfunction: Reduced clearance of all benzodiazepines 1
• Renal failure:
  • Increased lorazepam half-life and duration of effect 1
  • Active metabolite accumulation (midazolam, diazepam) 1
  • Dramatically prolonged awakening times 2

Cardiovascular/Respiratory Instability

Benzodiazepines cause respiratory depression and hypotension, especially when combined with opioids 1. Risk is highest in patients with baseline respiratory insufficiency or cardiovascular instability 1.

Clinical Outcomes Impact

Multiple studies demonstrate that prolonged benzodiazepine use worsens ICU outcomes 1:

• Prolonged mechanical ventilation duration
• Increased ICU and hospital length of stay
• Higher incidence of delirium
• Increased long-term cognitive dysfunction
• More days in coma 4

The COVID-19 pandemic highlighted these risks: deeper sedation with benzodiazepines was independently associated with prolonged coma, increased delirium, and higher mortality 5.

Withdrawal Syndrome Risk

Prolonged benzodiazepine infusions create risk for iatrogenic withdrawal syndrome 6. This complication requires recognition and appropriate tapering protocols to prevent negative outcomes during and after ICU discharge.

Guideline-Based Recommendations

The 2018 PADIS guidelines suggest using nonbenzodiazepine sedatives (propofol or dexmedetomidine) over benzodiazepines in critically ill, mechanically ventilated adults 7. This conditional recommendation is based on:

• Improved short-term outcomes (ICU LOS, ventilation duration, delirium)
• Better long-term outcomes (mortality, cognitive/physical functioning)

For cardiac surgery patients specifically: Propofol is preferred over benzodiazepines, showing 1.4 hours shorter time to extubation 7.

Critical Pitfalls to Avoid

1. Do not assume short-term use is safe: Even 1-2 days of lorazepam can cause delayed emergence 1
2. Do not ignore osmol gap monitoring with lorazepam infusions—toxicity occurs at lower doses than previously recognized 1
3. Do not use continuous infusions when intermittent dosing suffices: Continuous infusion specifically increases delirium risk 3
4. Do not overlook renal/hepatic function: These dramatically alter pharmacokinetics 1, 2
5. Do not combine with opioids without careful monitoring: Synergistic cardiopulmonary depression 1

Mechanistic Concerns

Emerging evidence suggests benzodiazepines may impair host immune defenses, exacerbate organ dysfunction, and accelerate "iatrogenic aging" by antagonizing adaptive stress responses like autophagy 8. This may contribute to post-intensive care syndrome (PICS) and post-sepsis syndrome.